![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
R Ganapathi, A Constantinou, N Kamath, G Dubyak, D Grabowski and K Krivacic
Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195, USA.
Tumor cell resistance to anthracyclines and epipodophyllotoxins can be due to reduced drug accumulation and/or alterations in the activity of topoisomerase II (TOPO II). HL-60 cells selected in 0.05 micrograms/ml doxorubicin (DOX) are 10-fold and > 20-fold resistant to DOX and etoposide (VP-16), respectively. The accumulation of [3H]VP-16 was 2-3- fold lower in the resistant cells (HL-60/DOX 0.05) than in similarly treated parent-sensitive cells (HL-60/S). However, compared with HL- 60/S cells, the HL-60/DOX 0.05 cells required > 20-fold higher concentrations of VP-16 to produce equivalent damage to DNA. The reduced formation of VP-16-stabilized DNA cleavable complex in the HL- 60/DOX 0.05 cells was not due to differences in the amount of 170-kDa TOPO (alpha) II protein or enzyme catalytic activity between HL-60/S and HL-60/DOX 0.05 cells. Metabolic labeling with [32P]orthophosphoric acid and immunoprecipitation indicated that the level of phosphorylated 170-kDa TOPO II alpha protein in the HL-60-/S cells was 2.2 +/- 0.4- fold higher than that in HL-60/DOX 0.05 cells. Hypophosphorylation (3- fold) of 170-kDa TOPO II protein in HL-60/S cells treated with the calcium chelator 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester produced a > 2-fold reduction in VP-16-induced TOPO II-mediated DNA cleavable complex formation. Two-dimensional mapping of phosphopeptides in complete tryptic digests demonstrated that the reduced phosphorylation of the 170-kDa TOPO II alpha in HL- 60/DOX 0.05 cells was due to the hypophosphorylation of at least three phosphopeptides characteristic of HL-60/S cells. Thus, the attenuated ability of TOPO II to form drug-stabilized DNA cleavable complex is related to the phosphorylated state of 170-kDa TOPO II, and in HL- 60/DOX 0.05 cells, resistance may be related to hypophosphorylation of three phosphopeptides characteristic of HL-60/S cells.
This article has been cited by other articles:
|
|
 |
|
  K. Chikamori, D. R. Grabowski, M. Kinter, B. B. Willard, S. Yadav, R. H. Aebersold, R. M. Bukowski, I. D. Hickson, A. H. Andersen, R. Ganapathi, et al. Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIalpha Regulates Enzymatic Activity and Drug Sensitivity J. Biol. Chem., April 4, 2003; 278(15): 12696 - 12702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Hazlehurst, N. Valkov, L. Wisner, J. A. Storey, D. Boulware, D. M. Sullivan, and W. S. Dalton Reduction in drug-induced DNA double-strand breaks associated with {beta}1 integrin-mediated adhesion correlates with drug resistance in U937 cells Blood, September 15, 2001; 98(6): 1897 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Stacey, M. Hitomi, and G. Chen Influence of Cell Cycle and Oncogene Activity upon Topoisomerase IIalpha Expression and Drug Toxicity Mol. Cell. Biol., December 15, 2000; 20(24): 9127 - 9137. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Oloumi, S. H. MacPhail, P. J. Johnston, J. P. Banáth, and P. L. Olive Changes in Subcellular Distribution of Topoisomerase II{{alpha}} Correlate with Etoposide Resistance in Multicell Spheroids and Xenograft Tumors Cancer Res., October 1, 2000; 60(20): 5747 - 5753. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. R. Grabowski, K. A. Holmes, M. Aoyama, Y. Ye, L. A. Rybicki, R. M. Bukowski, M. K. Ganapathi, I. D. Hickson, and R. Ganapathi Altered Drug Interaction and Regulation of Topoisomerase IIbeta : Potential Mechanisms Governing Sensitivity of HL-60 Cells to Amsacrine and Etoposide Mol. Pharmacol., December 1, 1999; 56(6): 1340 - 1345. [Abstract] [Full Text]
|
|
|
|
|
|
M. Aoyama, D. R. Grabowski, R. J. Isaacs, K. A. Krivacic, L. A. Rybicki, R. M. Bukowski, M. K. Ganapathi, I. D. Hickson, and R. Ganapathi Altered Expression and Activity of Topoisomerases During All-Trans Retinoic Acid-Induced Differentiation of HL-60 Cells Blood, October 15, 1998; 92(8): 2863 - 2870. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
